Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A new study finds that adding doravirine to existing HIV treatment can dramatically improve virologic control — but timing matters. People with a recent viral rebound saw an 88% success rate, while those with prolonged low-level viremia fared much worse at just 33%. The key factor? How active the background drug regimen is.
A multicenter observational study published in the Journal of Antimicrobial Chemotherapy found that adding doravirine to existing antiretroviral therapy (ART) can be a powerful tool for people living with HIV who are experiencing virologic failure — but its effectiveness depends heavily on when it's used and how active the rest of the regimen is.
The study enrolled 123 people living with HIV, split into two groups: those with a recent viral rebound (Group A, n=84) and those with prolonged low-level viremia lasting over a year (Group B, n=39). Virologic success at 6 months was evaluated based on achieving a viral load below 50 copies/mL.
Group A saw impressive results, while Group B struggled — and resistance mutations were more common in the prolonged viremia group, raising concerns about using this strategy too late.
By the Numbers:
Why it matters: This study gives clinicians a clearer roadmap for when adding doravirine makes sense. Acting early — at the first sign of viral rebound — yields far better outcomes than waiting through prolonged low-level viremia, where resistance risk climbs significantly.
